Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Pharma-Bio Serv, Inc. | pbsv_8k.htm |
Exhibit
99.1
Pharma-Bio Serv Announces Results for the Year Ended October 31,
2019
January 29, 2020
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2020 /
Pharma-Bio Serv, Inc. ("Pharma-Bio
Serv" or the "Company") (OTCQB: PBSV), a compliance, project
management and technology transfer support consulting firm that
provides services to the pharmaceutical, biotechnology, chemical,
medical device, cosmetic, food and allied products industries,
today announced revenues from continuing operations for the year
ended October 31, 2019 were $19.5 million, an increase of $1.7
million, or 9.6%, when compared to last year.
Net income from continued operations for the year ended October 31,
2019 was approximately $2.1 million, an improvement of $3.3 million
when compared to last year. This improvement includes last
year’s non-recurring 2018 US Tax Reform $2.7 million
Transition Tax charge recorded in February 2018.
In September 2018, we sold the assets of our laboratory segment.
After considering last fiscal year’s $2.5 million net income
from discontinued operations and related gain on segment
disposal and
last year’s non-recurring 2018 US Tax Reform Transition Tax,
our net income for the year ended October 31, 2019 of approximately
$2.1 million had an improvement in earnings of approximately $0.8
million over last year’s earnings.
“We are satisfied with the results we obtained by focusing
our operations on our consulting portfolio of services. We will
continue pursuing opportunities for growth which will enhance our
Company’s value. Finally, we were delighted to provide a
dividend of approximately $1.7 million to our loyal shareholders in
November 2019," said Victor Sanchez, CEO of Pharma-Bio Serv,
Inc.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv is a compliance, project management, and technology
transfer support consulting firm, headquartered in Puerto Rico,
with operations in the U.S., Ireland, and Spain. Pharma-Bio Serv's
core business is FDA and other international regulatory compliance
agency related services. The Company's global team includes leading
engineering and life science professionals, quality assurance
managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the
meaning of the U.S. federal securities laws, which statements may
include information regarding the plans, intentions, expectations,
future financial performance, or future operating performance of
Pharma-Bio Serv. Forward-looking statements are based on the
expectations, estimates, or projections of management as of the
date of this news release. Although Pharma-Bio Serv's management
believes these expectations, estimates, or projections to be
reasonable as of the date of this news release, forward-looking
statements are inherently subject to significant business risks,
economic and competitive uncertainties, or other contingencies,
which could cause its actual results or performance to differ
materially from what may be expressed or implied in the
forward-looking statements. Important factors that could cause
Pharma-Bio Serv's actual results or performance to differ
materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual
Report on Form 10-K for the year ended October 31, 2019, and in its
other filings with the Securities and Exchange Commission, which
filings are available on www.sec.gov.
Pharma-Bio Serv disclaims any intention or obligation to update or
revise any forward-looking statements to reflect subsequent events
and circumstances, except to the extent required by applicable
law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv,
Inc.